"Combining AbbVie's leadership and deep expertise in monoclonal antibody discovery, development and commercialization and our ability to
vectorize monoclonal antibodies is a natural fit, and we are very pleased to collaborate with AbbVie to advance this strategy towards the clinic in an effort to bring innovative treatments to patients," said Steven Fhul, M.D., president and chief executive officer of Voyager.